Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer

Narrative review of cytoreductive surgery and intraperitoneal chemotherapy for peritoneal metastases in ovarian cancer

“…The use of IV/IP chemotherapy was associated with a significantly increased PFS and OS compared to the IV-only treatment (23.8 vs. 18.3 months, respectively, P=0.05; and 65.6 vs. 49.7 months, respectively, P=0.03) (6). A retrospective analysis by Suidan et al reported similar findings of improved PFS and OS with IP therapy regardless of number of cycles (8). The authors analyzed 201 patients with stage III-IV epithelial ovarian cancer who underwent primary debulking surgery and achieved optimal cytoreduction followed by 1 or more cycles of IV/IP chemotherapy and were not able to detect a survival benefit for patients receiving 5-6 cycles versus 3-4 cycles or even 1-2 cycles.…”